Novo's Awiqli® receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes
Awiqli® offers children 10 years and older a once-weekly basal insulin alternative, reducing basal injection frequency from seven times per week to one1 As type 2 diabetes incidence rates among youth continue to rise,² Awiqli® may help reduce administration barriers associated with daily...
This is a short summary. The full story is published by Pr Newswire.
Read full story at Pr Newswire
